• Home
  • Search Results
  • Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.

Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.

Blood (2015-03-15)
Antonella Mancusi, Loredana Ruggeri, Elena Urbani, Antonio Pierini, Maria Speranza Massei, Alessandra Carotti, Adelmo Terenzi, Franca Falzetti, Antonella Tosti, Fabiana Topini, Silvia Bozza, Luigina Romani, Rita Tognellini, Martin Stern, Franco Aversa, Massimo F Martelli, Andrea Velardi
ABSTRACT

Because activating killer cell immunoglobulinlike receptors (KIRs) are heterogeneously expressed in the population, we investigated the role of donor activating KIRs in haploidentical hematopoietic transplants for acute leukemia. Transplants were grouped according to presence vs absence of KIR-ligand mismatches in the graft-vs-host direction (ie, of donor-vs-recipient natural killer [NK]-cell alloreactivity). In the absence of donor-vs-recipient NK-cell alloreactivity, donor activating KIRs had no effects on outcomes. In the 69 transplant pairs with donor-vs-recipient NK-cell alloreactivity, transplantation from donors with KIR2DS1 and/or KIR3DS1 was associated with reduced risk of nonrelapse mortality, largely infection related (KIR2DS1 present vs absent: hazard ratio [HR], 0.25; P = .01; KIR3DS1 present vs absent: HR, 0.18; P = .006), and better event-free survival (KIR2DS1 present vs absent: HR, 0.31; P = .011; KIR3DS1 present vs absent: HR, 0.30; P = .008). Transplantation from donors with KIR2DS1 and/or KIR3DS1 was also associated with a 50% reduction in infection rate (P = .003). In vitro analyses showed that KIR2DS1 binding to its HLA-C2 ligand upregulated inflammatory cytokine production by alloreactive NK cells in response to infectious challenges. Because ∼40% of donors able to exert donor-vs-recipient NK-cell alloreactivity carry KIR2DS1 and/or KIR3DS1, searching for them may become a feasible, additional criterion in donor selection.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Granulocyte-Macrophage Colony-Stimulating Factor human, GM-CSF, recombinant, expressed in E. coli, suitable for cell culture
Sigma-Aldrich
Granulocyte-Macrophage Colony-Stimulating Factor from mouse, GM-CSF, from mouse, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
6-Phosphonohexanoic acid, 97%
Sigma-Aldrich
Granulocyte-Macrophage Colony-Stimulating Factor human, GM-CSF, Animal-component free, recombinant, expressed in E. coli, suitable for cell culture
Sigma-Aldrich
Granulocyte-Macrophage Colony-Stimulating Factor human, GM-CSF, recombinant, expressed in HEK 293 cells, HumanKine®, suitable for cell culture
Sigma-Aldrich
Granulocyte-Macrophage Colony-Stimulating Factor from rat, GM-CSF, recombinant, expressed in E. coli

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.